Dr. Elkordy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
216 Ashville Ave
Cary, NC 27511Phone+1 919-854-6900Fax+1 919-784-6828
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1991 - 1994
- University of North Carolina HospitalsResidency, Internal Medicine, 1988 - 1991
- University of North Carolina at Chapel Hill School of MedicineClass of 1988
Certifications & Licensure
- NC State Medical License 1989 - 2021
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Top MD Consumers Checkbook
Publications & Presentations
PubMed
- 11 citationsResults of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?William R. Berry, Maha Elkordy, Mark A. O'Rourke, Myrna Khan, Lina Asmar
Cancer Investigation. 2007-02-01 - 2 citationsPhase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu–Negative Metastatic Breast Cancer: A Community-Based StudyDavid M. Loesch, Nicholas J. Robert, Stephen E. Jones, Maha Elkordy, Des Ilegbodu
Journal of Oncology Practice. 2006-11-01 - 53 citationsPrognostic and Predictive Factors for Patients With Metastatic Breast Cancer Undergoing Aggressive Induction Therapy Followed by High-Dose Chemotherapy With Autologous...David A. Rizzieri, James J. Vredenburgh, Robert Henry Jones, Maureen Ross, Elizabeth J. Shpall
Journal of Clinical Oncology. 1999-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: